Authors: Xu, M Li, J Gulfo, JV Von Hofe, E Humphreys, RE

Citation: M. Xu et al., MHC class II allosteric site drugs: New immunotherapeutics for malignant, infections and autoimmune diseases, SC J IMMUN, 54(1-2), 2001, pp. 39-44

Authors: Humphreys, RE Adams, S Koldzic, G Nedelescu, B von Hofe, E Xu, M

Citation: Re. Humphreys et al., Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide, VACCINE, 18(24), 2000, pp. 2693-2697

Authors: Xu, MZ Qiu, G Jiang, Z von Hofe, E Humphreys, RE

Citation: Mz. Xu et al., Genetic modulation of tumor antigen presentation, TRENDS BIOT, 18(4), 2000, pp. 167-172

Authors: Qiu, G Goodchild, J Humphreys, RE Xu, MZ

Citation: G. Qiu et al., Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells, CANCER IMMU, 48(9), 1999, pp. 499-506

Authors: Xu, MZ Jackson, R Adams, S Humphreys, RE

Citation: Mz. Xu et al., Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1, ARZNEI-FOR, 49(9), 1999, pp. 791-799